Salesforce To $240? Plus RBC Capital Boosts PT For Autodesk

Jefferies cut the price target on Salesforce, Inc. (NYSE: CRM) from $250 to $240. Jefferies analyst Brent Thill maintained the stock with a Buy rating. Salesforce shares fell 1.2% to trade at $146.20 on Monday.
  • Jefferies cut the price target on Salesforce, Inc. (NYSE:CRM) from $250 to $240. Jefferies analyst Brent Thill maintained the stock with a Buy rating. Salesforce shares fell 1.2% to trade at $146.20 on Monday.
  • Barclays boosted the price target for SAP SE (NYSE:SAP) from $106 to $136. SAP shares rose 0.8% to trade at $109.68 on Monday.
  • Credit Suisse raised the price target on CVS Health Corporation (NYSE:CVS) from $117 to $125. CVS Health shares rose 0.6% to trade at $97.95 on Monday.
  • RBC Capital boosted the price target on Autodesk, Inc. (NASDAQ:ADSK) from $257 to $260. Autodesk shares fell 1.2% to $207.93 on Monday.
  • Citigroup raised the price target for Atkore Inc. (NYSE:ATKR) from $94 to $117. Atkore shares rose 1% to trade at $117.14 on Monday.

Check out this: 5 On-The-Money Stock Picks For Last Week From Benzinga’s Most Accurate Analysts

Total
0
Shares
Related Posts
Read More

TransMedics Stock Skyrockets, Analysts Call It ‘One Of The Best Organic Growth Stories’

TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-$400 million. Analysts hail TransMedics' organic growth and strong market position, praising its innovative solutions and promising prospects.

TMDX